PreTRM Global

Product

Last mentioned: Mar 19, 2026

Timeline

  1. Cash Runway Limit

    Current capital projected to fund operations through this period across commercial milestones.

  2. Commercial Target

    Goal to reach 15-17 states and 5-7 live partner programs.

  3. Q4 Earnings Call

    Management confirms runway through 2028 and details PRIME study impact.

  4. Fiscal Year End

    Sera concludes 2025 with $95.8M in cash and a narrowed net loss.

Stories mentioning PreTRM Global 1

pharma Bullish

Sera Prognostics Leverages PRIME Study Success for 2028 Commercial Runway

Sera Prognostics reported a narrowed annual net loss of $31.9 million for 2025, supported by a robust $95.8 million cash position that extends its operational runway into 2028. The company is pivoting toward large-scale commercialization of its PreTRM test following landmark PRIME study data showing a 56% reduction in very early preterm births.

6 sources